CRNX vs CHRS vs RCUS vs ESPR vs HALO

For growth investors, Crinetics Pharmaceuticals, Inc.

(CRNX) is the stronger pick with 640. 7% revenue growth year-over-year, versus -84. 2% for Coherus Oncology, Inc. (CHRS). Coherus Oncology, Inc. (CHRS) offers the better valuation at 1. 2x trailing P/E, making it the more compelling value choice. Analysts rate Crinetics Pharmaceuticals, Inc. (CRNX) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Coherus Oncology, Inc.

(CHRS) is the cheapest at 1. 2x versus Halozyme Therapeutics, Inc. at 25. 5x.

Over the past 5 years, Crinetics Pharmaceuticals, Inc.

(CRNX) delivered a total return of +156. 3%, compared to -87. 7% for Coherus Oncology, Inc. (CHRS). Over 10 years, the gap is even starker: HALO returned +570. 7% versus CHRS's -90. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Esperion Therapeutics, Inc. 's 2. 33β — meaning ESPR is approximately 317% more volatile than HALO relative to the S&P 500. On balance sheet safety, Coherus Oncology, Inc. (CHRS) carries a lower debt/equity ratio of 2% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Crinetics Pharmaceuticals, Inc.

(CRNX) is pulling ahead at 640. 7% versus -84. 2% for Coherus Oncology, Inc. (CHRS). On earnings-per-share growth, the picture is similar: Coherus Oncology, Inc. grew EPS 472. 0% year-over-year, compared to -34. 1% for Crinetics Pharmaceuticals, Inc.. Over a 3-year CAGR, ESPR leads at 74. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coherus Oncology, Inc.

(CHRS) is the more profitable company, earning 398. 4% net margin versus -60. 5% for Crinetics Pharmaceuticals, Inc. — meaning it keeps 398. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -67. 1% for CRNX. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CHRS: 242.

0% to $6. 02.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Coherus Oncology, Inc. (CHRS) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +570. 7%, CHRS: -90. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CRNX is a small-cap high-growth stock; CHRS is a small-cap deep-value stock; RCUS is a small-cap quality compounder stock; ESPR is a small-cap high-growth stock; HALO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.